Wolves Could Be an Unlikely Hero in the Fight to Save Humanity
Grey wolves were excised from Scotland roughly 250 years ago, ending decades of attempted eradication.
Fortunately for Scotland's climate, reintroducing wolves to the region could lead to native woodland growth and increased CO2 sequestration.
Large carnivores, in fact, may be a nature-based solution to parts of the climate crisis.
When we learn about ecosystems in elementary school, we're taught that animals at the top of the food chain (lions, tigers, alligators, etc...) have no natural predators. As a result it can be hard to fathom that some of their populations have declined to the point of extinction—until, that is, you remember humans. We humans aren't considered 'natural predators,' but we are largely responsible for the disappearance of these ecological kings in many regions.
Wolves, in particular, have a long history of being tormented by humans. According to the UK Wolf Conservation Trust, the earliest extermination record in Scotland dates back to 1238, when an allowance was paid to 'one hunter of wolves.' One king—James I of Scotland—passed an act in 1427 requiring all lords to seek out and kill wolves. In later years, the Earl of Atholl held multiple wolf hunts.
Despite being routinely slaughtered, wolves persevered in Scotland until roughly 250 years ago. Now, a new study published in the journal Ecological Solutions and Evidence suggests reintroducing them to the region may drastically reduce carbon dioxide levels.
It may seem counterintuitive at first. After all, why would adding another species that eats and breathes have positive effects on CO2 levels? Well, it all goes back to the food chain.
The study explains that apex predators play their role in the carbon cycle by controlling wild herbivore populations. In Scotland, the population of red deer has soared as high as 400,000 (that's roughly one deer for every 14 people in the country) without grey wolves hunting them. Deer, and in certain areas sheep, prevent tree saplings from growing across the region.
According to the study, reintroducing large carnivores to control deer abundance could lead to woodland expansion that would absorb up to 1 million metric tonnes of CO2 each year. This would make up 5% of the carbon removal target for United Kingdom woodlands. At the current cost of carbon dioxide removal and storage, the team estimates each wolf would be worth up to £154,000 (roughly $194,000 USD) per year—though, the estimate doesn't include the initial cost required to reestablish the population. The study also doesn't consider how changing herbivore dynamics and woodland expansion could affect soil carbon.
'There is an increasing acknowledgement that the climate and biodiversity crises cannot be managed in isolation,' Dominick Sprackled, lead author of the study, said in a press release. 'We need to look at the potential role of natural processes such as the reintroduction of species to recover our degraded ecosystems and these in turn can deliver co-benefits for climate and nature recovery.'
The study isn't without controversy, however. Conflict between humans and large predators is a major point of contention, as reintroducing carnivores could potentially interfere with activities like raising livestock.
'We recognize that substantial and wide-ranging stakeholder and public engagement would clearly be essential before any wolf reintroduction could be considered,' the researchers wrote. 'Human-wildlife conflicts involving carnivores are common and must be addressed through public policies that account for people's attitudes for a reintroduction to be successful.'
You Might Also Like
The Do's and Don'ts of Using Painter's Tape
The Best Portable BBQ Grills for Cooking Anywhere
Can a Smart Watch Prolong Your Life?

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Report: Multispecific Antibodies Market to Surpass USD 50 Billion by 2030
Explore the booming Global Multispecific Antibodies Market set to surpass USD 50 billion by 2030. Key highlights include sales insights, approved drugs, and clinical trials from over 700 antibodies. Significant contributors like Roche and rising players ensure ongoing innovation in this dynamic biopharma sector. Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Global Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Insight 2030" report has been added to Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Insight 2030 Report Highlights: Global Multispecific Antibodies Market Opportunity By 2030: > USD 50 Billion Global Multispecific Antibodies Market Sales In 2024: > USD 12 Billion Number Of Approved Multispecific Antibodies: 18 Global & Regional Trends Insight Approved Antibodies Global, Regional, Annual & Quarterly Sales Insight Approved Antibodies Dosage & Pricing Insight Comprehensive Insight On All Antibodies In Clinical Trials By Company, Country, Indication & Phase Number Of Multispecific Antibodies: In Clinical Trials: > 700 Multispecific antibodies market globally has been one of the most energetic and fast growing sectors in the biopharmaceutical business as a result of therapeutic breakthroughs and growing acceptance of their ability to treat complicated pathologies by targeting multiple pathways simultaneously. As of May 2025, 18 multispecific antibodies have gained regulatory approval globally, all of which are bispecific constructs, a monumental milestone in the history of targeted therapeutics. This expanding portfolio boasts trailblazing drugs like Blincyto, the first bispecific antibody to gain approval, and Hemlibra, which was the first bispecific antibody to be approved for a non-cancer indication. The latest entrant to this therapeutic pipeline is Regeneron's Lynozyfic, which received marketing approval in April 2025 for the treatment of multiple myeloma, with evidence of ongoing momentum in the segment. The range of approved multispecific antibodies mirrors the flexibility of this therapeutic modality across various disease indications and patient bases. Rybrevant is another key breakthrough as the first bispecific antibody for a solid tumor, whereas China based Akeso's Cadonilimab is especially noteworthy for being solely approved bispecific antibody intended to target two immune checkpoints at once and becoming the first China developed bispecific antibody to gain regulatory approval. This regional variation in development emphasizes the world nature of innovation in this sector, with input from both mature pharmaceutical markets and developing biotechnology centers. The regulatory environment is still changing at a rapid pace, with further approvals expected in the near future. The FDA is also evaluating marketing applications for Odronextamab and Linvoseltamab, both of which have already received approval in the EU for follicular lymphoma and diffuse large B-cell lymphoma, and multiple myeloma, respectively. Such transatlantic regulatory advancements reflect the growing acceptability and trust in multispecific antibody technologies by global regulatory bodies. Market performance has been extremely strong, with global multispecific antibodies market sales in 2024 amounting to over US$ 12.6 Billion, followed by first quarter 2025 sales of over US$ 3.46 Billion. The US is the largest contributor to these sales, highlighting the maturity and acceptance of the market in this prime geography. Roche's mature products, Hemlibra and Vabysmo, lead the market share, with over half of total sales, emphasizing the value of first mover benefit and effective market entry strategies in this competitive market. The pipeline for development is an even more daunting picture, with more than 900 multispecific antibodies already in various stages of development. Oncology is leading this pipeline, both due to the traditional priority of multispecific antibody development and due to the large unmet medical needs in cancer treatment. However, pipeline diversity is not confined to oncology alone with promising candidates being identified in autoimmune and inflammatory diseases and neurological disorders as well, indicating an expanding therapeutic horizon that has the potential to dramatically expand market opportunities. Major industry players behind this innovation are well established pharma giants like Amgen, AstraZeneca, Genentech, and Regeneron, as well as new biotech firms like ABL Bio, Harbour BioMed, Innovent Biologics, Merus, and Zymeworks. This combination of well established and new players provides a vibrant competitive landscape that ensures ongoing innovation and technological progress. Strategic alliances continue to influence the development of the market, such as in the April 2025 alliance of Boehringer Ingelheim and Cue Biopharma for the development of CUE-501, a bispecific candidate that attacks pathogenic B cells via virus-specific memory T cells. The alliance, involving a US$ 12 Million upfront payment and possible milestone payments of up to US$ 345 Million, illustrates the high financial investment that companies are undertaking to drive multispecific antibody technologies, specifically in autoimmune indications where existing treatments are still inadequate. Regulatory encouragement of innovation continues to be robust, with the FDA's April 2025 fast track designation of ISB 2001, an Ichnos Glenmark Innovation investigational trispecific T-cell engager for relapsed or refractory multiple myeloma, reflecting ongoing regulatory enthusiasm for moving multispecific antibody technologies forward that treat important unmet medical needs. As a result of these ongoing innovations, the global multispecific antibody market is expected to grow rapidly and is on track to become one of the most important segments within the pharmaceutical industry. Key Topics Covered: 1. Introduction to Next Generation Multispecific Antibodies 2. Next Generation Multispecific Antibody Current Clinical Development & Future Commercialization Outlook2.1 Current Market Overview2.2 Future Commercialization Opportunity2.3 Collaborations, License Agreements, Investments & Acquisitions2.4 Next Generation Multispecific Antibody Proprietary Technologies By Company 3. Next Generation Multispecific Antibody Clinical Trends by Indication3.1 Cancer3.2 Hematological Disorders3.3 Microbial Infections3.4 Autoimmune & Inflammatory Disorders3.5 Ocular Diseases 4. Next Generation Multispecific Antibody Clinical Development & Market Trends by Region4.1 US4.2 EU4.3 China4.4 UK4.5 Japan4.6 Australia4.7 South Korea4.8 Canada 5. Approved Multispecific Antibodies - Clinical Overview, Pricing & Dosage Insight5.1 Overview5.2 Clinical Overview, Pricing & Dosage Insight 6. Approved Multispecific Antibodies - Sales Insight (2020 - Q1'2025) 7. Global Multispecific Antibodies Clinical Trials Overview 8. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase8.1 Research8.2 Preclinical8.3 Phase-I8.4 Phase-I/II8.5 Phase-II8.6 Phase-II/III8.7 Phase-III8.8 Preregistration8.9 Registered 9. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication 10. Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase10.1 Research10.2 Preclinical10.3 Phase I10.4 Phase I/II10.5 Phase II/III 11. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase11.1 Preclinical11.2 Phase I11.3 Phase I/II11.4 Phase II 12. Competitive Landscape AbbVie ABL Bio Abzyme Therapeutics Affimed Therapeutics Akeso Biopharma Alligator Bioscience Amgen Antibody Therapeutics APITBIO Astellas Pharma AstraZeneca Aptevo Therapeutics BioAtla Biocytogen Pharmaceuticals Biosion EpimAb Biotherapeutics FutureGen Biopharmaceutical Genentech Genmab Genor Biopharma Gensun Biopharma Harbour BioMed IGM Biosciences I-MAB Biopharma ImmuneOnco Biopharma ImmunoPrecise Antibodies Innate Pharma Innovent Biologics Invenra Johnson & Johnson Kenjockety Biotechnology LaNova Medicines Limited Light Chain Bioscience Linton Pharm Lyvgen Biopharma MacroGenics Merck Merus ModeX Therapeutics (OPKO Health) Molecular Partners NovaRock Biotherapeutics Numab OPKO Health Pfizer Regeneron Pharmaceuticals Revitope Roche Sanofi Sichuan Baili Pharmaceutical SystImmune Virtuoso Therapeutics Xencor Y-Biologics Zhejiang Shimai Pharmaceutical Zymeworks For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
STEM Education in K–12 Market to Reach USD 168.63 Billion by 2032 Driven by Digital Transformation and Early STEM Integration
STEM Education in K–12 is rapidly expanding, driven by digital learning, early intervention, and growing demand for future-ready skills. Pune, June 13, 2025 (GLOBE NEWSWIRE) -- STEM Education in K–12 Market Size Analysis: 'The STEM Education in K–12 market was valued at USD 51.42 billion in 2023 and is projected to grow to USD 168.63 billion by 2032, registering a CAGR of 14.17% during the forecast period from 2024 to 2032.'Get a Sample Report of STEM Education in K–12 Market@ Major Players Analysis Listed in this Report are: Activate Learning Amplify Education, Inc. Bedford, Freeman & Worth Publishing Group, LLC Carolina Biological Supply Company Cengage Learning Discovery Education EduCo International Houghton Mifflin Harcourt Kendall Hunt Publishing Company Lab-Aids McGraw Hill OpenSciEd PASCO Scientific Savvas Learning School Specialty, LLC STEM Education in K–12 Market Report Scope: Report Attributes Details Market Size in 2023 US$ 51.48 Billion Market Size by 2032 US$ 168.63 Billion CAGR CAGR of 14.17% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Key Segments • By Type (Self-paced, Instructor-led)• By Application (Elementary School (K-5), Middle School (6-8), High School (9-12)) Key Growth Drivers Rising demand for future-ready skills is prompting K-12 institutions to embed STEM learning early in academic curriculums. Do you have any specific queries or need any customization research on STEM Education in K–12 Market, Make an Enquiry Now@ Factors such as growing education technology adoption, increasing demand for digital technology learning tools, and increased acknowledgment of STEM skills for the future workforce are accelerating this growth. Along with government initiatives, public-private partnerships, and reforms in curriculum that push STEM literacy are also playing a role. Further, the growth of online and blended learning platforms is making STEM education increasingly more accessible and attractive to students worldwide. The U.S. STEM Education in K–12 market was valued at USD 14.12 billion in 2023 and is anticipated to reach USD 46.26 billion by 2032, expanding at a CAGR of 14.09% from 2024 to 2032. Growth is fueled by increasing emphasis on future-ready skills, federal funding for STEM programs, and the widespread adoption of digital learning tools in classrooms. By Type, Self-Paced Learning Segment Dominated the STEM Education in K–12 Market, Instructor-Led Segment to Witness Fastest Growth In 2023, the self-paced learning segment held the largest share around 70% in the K–12 STEM education market. This dominance is due to its flexibility, scalability, and compatibility with digital platforms. Personalized speed helps students progress through difficult topics with greater understanding. Schools like it because it is affordable, low on instructor dependence, and easy to implement across different grades and geographies. The instructor-led segment is projected to grow at the fastest CAGR of 15.87% during 2024–2032, driven by rising demand for interactive, structured STEM learning. The real-time feedback, guidance from experts and activities that encourage collaboration and peer-to-peer interactions can help you hone these skills in problem-solving and critical thinking. As high-quality STEM education continues its upward trajectory, school districts and parents prefer instructor-led approaches for their depth and engagement. By Application, High School (Grades 9–12) Segment Led the STEM Education in K–12 Market, Middle School (Grades 6–8) Segment Projected to Grow at Fastest CAGR In 2023, the high school segment accounted for the largest share—about 42%—in the STEM Education in K–12 market. That dominance stems from extensive college and career readiness. Through a system of specialized labs, industry-linked programs and competitions, students learn higher concepts of STEM subjects as schools to compete against each other to prepare students to pursue advanced programs in colleges and tech-oriented careers as adults. The middle school segment is poised for the fastest growth at a 15.60% CAGR during 2024–2032, fueled by increased early STEM education efforts. Tools that are interactive, gamified platforms, and early exposure to coding and robotics get students interested. Educators aspire to build STEM pipelines well ahead of adults entering the job market, and this initial phase is critical to motivating for lifelong engagement with an Enterprise-User PDF of STEM Education in K–12 Market Analysis & Outlook 2024-2032@ North America Dominated the K–12 STEM Education Market, Asia Pacific Region to Record Fastest CAGR In 2023, North America led the STEM Education in K–12 market with a 39% revenue share, due to institutional support, a well-advanced digital infrastructure, and education funding. Early technology exposure, strong school curriculum adoption, and collaboration of schools with technology companies and governments contribute to the strength of the region. Also, North America is well ahead in STEM education in part due to a combination of intense teacher training and the availability of modern learning tools. The Asia Pacific region is projected to experience the fastest growth at a 15.83% CAGR between 2024 and 2032, fueled by rising government support and expanding education budgets. Countries like China, India, and South Korea are aggressively promoting STEM through national curricula. Rapid digital adoption, growing student populations, and rural education investments alongside booming interest in tech careers—are propelling the region's expansion in K–12 STEM education. About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)


Business Upturn
2 days ago
- Business Upturn
Flow Cytometry Market Hits US$10.3B by 2032: Why Every Lab Needs a FACS Flow Cytometer?
Delray Beach, FL, June 13, 2025 (GLOBE NEWSWIRE) — Ever wondered how scientists peek inside our cells, analyzing their secrets to diagnose diseases or develop life-saving therapies? It's all thanks to flow cytometry, a dynamic field transforming healthcare and research. And at its core, the remarkable FACS flow cytometer market leads the charge, offering unparalleled precision in analyzing and sorting cells. Imagine a sophisticated, high-speed sorting machine for microscopic cells. That's essentially what a flow cytometer machine does, and the FACS flow cytometer excels, providing meticulous insights into everything from cell cycle flow to identifying disease-causing biomarkers. Download PDF Brochure: This market is exploding, projected to jump from US$5.1 billion in 2024 to US$10.3 billion by 2032, growing at a robust 9.2% CAGR. What's fueling this surge? Rapid technological advancements (especially in FACS flow cytometer systems), increasing adoption in clinical diagnostics, rising chronic disease rates, booming biopharmaceutical R&D, and the urgent demand for precision medicine. Even AI and machine learning are boosting data analysis, accelerating this growth. Why the Buzz? Opportunities & Challenges in Flow Cytometry The global flow cytometry market offers exciting opportunities, but it's not without hurdles: Drivers: Innovation Pushes Boundaries The market thrives on new, advanced flow cytometry products and flow cytometer machines. Manufacturers are focused on creating instruments that are powerful, user-friendly, and incredibly fast. A cutting-edge FACS flow cytometer can analyze and sort thousands of cells per second with unmatched accuracy. Recent innovations like multiplexing, higher throughput systems, and smarter data analysis software are making these tools indispensable. Case in point: In April 2024, Becton, Dickinson and Company launched the BD FACSDiscover S8 Cell Sorter. This advanced spectral cell sorter, a prime FACS flow cytometer, combines real-time imaging with spectral analysis—a game-changer for detailed cellular purification. Restraints: The Cost Barrier Despite the benefits, high costs pose a challenge. Labs often require many flow cytometry instruments, leading to significant capital and maintenance expenses. For academic & research laboratories with restricted budgets, affording a high-end FACS flow cytometer can be tough. A single flow cytometer machine can cost over USD 500,000, and FACS flow cytometer-based cell sorters are typically pricier than cell analyzers due to their precision. This cost can slow adoption, especially in emerging countries. Opportunities: Expanding Clinical Horizons Increased use in clinical applications and infectious disease diagnostics is a massive opportunity. A cell cytometer, particularly a precise FACS flow cytometer, is invaluable for disease diagnosis, prognosis, and monitoring. In hematology, it's key for leukemia and lymphoma diagnosis, identifying rare cancer cells. In immunology, it helps diagnose immunodeficiencies and autoimmune disorders. Example: In March 2024, Beckman Coulter's DxFLEX Clinical Flow Cytometer received USFDA clearance, validated for 10-color immunophenotyping for leukemia and lymphoma—a clear win for clinical FACS flow cytometer applications. Challenges: Reagent Complexity Complexities related to reagent development present a notable challenge. These reagents (like fluorescently labeled antibodies and dyes) are vital for any flow cytometer machine, including FACS flow cytometer systems. Creating high-quality, specific, and stable reagents is time-consuming and resource-intensive, requiring extensive testing to ensure accurate, reproducible results across diverse applications. Request Sample Pages: Who's Driving Growth? Market Segments & Global Leaders Reagents & Consumables: This segment dominated the flow cytometry market in 2023 , essential for any flow cytometer machine , especially advanced FACS flow cytometer systems. This segment dominated the , essential for any , especially advanced systems. Academic & Research Institutes: Poised for substantial growth, driven by increased investment in clinical trials, drug development, and a demand for high-throughput FACS flow cytometer capabilities. Poised for substantial growth, driven by increased investment in clinical trials, drug development, and a demand for high-throughput capabilities. North America: Led the global flow cytometry market in 2023 due to robust healthcare infrastructure, significant investment in research and development, and high adoption of advanced flow cytometry technologies. The Asia Pacific region is expected to show significant growth. Key market players like Becton, Dickinson and Company (US), Danaher Corporation (US), and Thermo Fisher Scientific Inc. (US) are continuously innovating, often focusing on new FACS flow cytometer models to strengthen their market position. Recent Developments: From Agilent's NovoCyte Opteon Spectral Flow Cytometer (May 2024) to Sony's FP7000 spectral cell sorter (October 2023) and BD's groundbreaking FACSDiscover S8 Cell Sorter (March 2023), these innovations highlight the rapid evolution of FACS flow cytometer technology. FAQs Shaping Industry Conversations: 1. What is the core purpose of a Flow Cytometer machine? A flow cytometer machine rapidly analyzes and sorts microscopic cells in fluid, using lasers to gather data on cell size, granularity, and specific markers via scattered light and fluorescence. Essential for both fundamental research and precise disease diagnosis. 2. How does a FACS Flow Cytometer elevate cellular analysis? A FACS flow cytometer goes beyond analysis. As an advanced cell cytometer, it physically separates and collects specific cell populations based on their characteristics. This allows for high-purity isolation of rare cells, crucial for in-depth research and therapeutic development. 3. Why is the global flow cytometry market experiencing such explosive growth? The global flow cytometry market is booming, projected to reach US$10.3 billion by 2032, driven by tech advancements (e.g., spectral analysis in FACS flow cytometer), rising adoption in clinical diagnostics, increasing chronic disease prevalence, and surging biopharmaceutical R&D. AI and machine learning further accelerate this expansion. 4. What are the key hurdles in adopting flow cytometry instruments? The main challenge is the high cost of instruments, often exceeding USD 500,000, especially for advanced FACS flow cytometer models. Complexities in reagent development also add to the operational cost, limiting adoption for smaller academic & research laboratories with restricted budgets. 5. How critical is flow cytometry in understanding cell cycle flow and diagnosing blood cancers? Flow cytometry is vital for studying cell cycle flow by analyzing cellular DNA content. Clinically, a FACS flow cytometer is indispensable for diagnosing hematological malignancies like leukemia and lymphoma, by precisely identifying and characterizing abnormal immune cell populations based on unique surface markers. For more information, Inquire Now! Related Reports: Single Cell Analysis Market Cell Based Assays Market Esoteric Testing Market Research Antibodies Market Cell Analysis Market Get access to the latest updates on Top Companies in Flow Cytometry and Flow Cytometry Market Size Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash